特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
911977

抗感染症薬の世界市場:成長、動向、および予測

Anti-infective Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 114 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.70円
抗感染症薬の世界市場:成長、動向、および予測
出版日: 2020年06月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 114 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートは世界の抗感染症薬市場について調査しており、市場機会や動向、成長および阻害要因、製品タイプ・適応症・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 成長要因
  • 阻害要因
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界内の競争

第5章 市場セグメント

  • 製品タイプ別
    • 抗生物質
    • 抗ウイルス薬
    • 抗真菌剤
    • その他
  • 適応症別
    • HIV
    • 肺炎
    • 呼吸器ウイルス感染
    • 敗血症
    • 結核
    • その他
  • 流通チャネル別
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Abbott Laboratories
    • Astellas Pharma Inc
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Gilead Sciences, Inc
    • GlaxoSmithKline PLC
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer, Inc
    • Sanofi SA

第7章 市場機会および今後の動向

目次
Product Code: 66831

Anti-infectives drugs has been one of the major segment for many pharmaceutical companies from decades. Over the past two decades, the infection rate has grown significantly, particularly across the low and middle income countries.

There are a large number of companies well-established in the market with their products in the form of antifungals, antibiotics, anti-bacterial, anti-protozoans and antivirals targeting cytochrome, interleukin, interferons and some are multi-drug resistants. The primary driving factor for the growth of the market is increasing burden of several infectious diseases across developed and emerging markets such as different forms of influenza, diarrhea, hepatitis, and urinary tract infections, among others, which needs more attention from pharmaceutical and biotechnology companies.

Moreover, there has been significant growth in the number of multidrug-resistant organisms across several parts of the world, which further increases the importance of innovation in the anti-infective agents.

However, some of the major restraints to this market are high investment costs in R&D, as major importance is given to multi-drug resistant drug, where several companies product fail in the early-stage or clinical stage of development. Also, shortage of resources in healthcare facilities particularly in emerging markets, restricts the growth of this market.

Key Market Trends

Antiviral Products are Expected to Register High Growth Over the Forecast Period

  • The anti-viral agents are expected to show high growth over the forecast period, as several drug manufacturers are exploring the opportunities to expand in the lower and middle income countries, where epidemic infection rate is high.
  • There is high diversity in patient pool which require long treatment procedures in hospital facilities as well as home care treatments.
  • Moreover, there has been observed a growing interest by government in countries showing fast economic growth, to collaborate with hospitals and global pharmaceutical companies to imporve the distribution rate of antiviral agents to the needful in the required area of a country. Such factors are expected to boost the growth of antivirals segment over the forecast period.

North America is Estimated to Have Largest Share Over the Forecast Period

With a sophisticated healthcare infrastructure, high awareness in the society, well-established distribution channels and good presence of e-commerce across the United States and Canada drives, helps North America to dominate this market over the forecast period.

The high purchasing power by the end consumer and favorable reimbursement policies helps pharmaceutical companies to grow in this region. Further, it helps the pharmacetical companies increase the production capabilities, invest more upon the funded projects with renowned medical institutions to suffice the demand of anti-infective drugs across North America.

Competitive Landscape

The major market players are focusing on better distribution channel as well as reaching out to each category of patients with different diseases and age groups, which makes the companies grow in this market. Some of the major players in the market are Novartis AG, Merck & Co., Inc, Sanofi SA, GSK, and Gilead Sciences, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Targeted Diseases
    • 4.2.2 Growing Initiatives for the Awareness of Infectious Diseases
    • 4.2.3 Increasing Investments on R&D Activities of Anti-Infective Drugs
  • 4.3 Market Restraints
    • 4.3.1 Emergence of Anti-infective Drugs Resistance and Side Effects Associated with Anti-infective drugs
    • 4.3.2 Shortage of Resources in Certain Low- and Middle-income Countries (LMIC)
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Antibiotics
    • 5.1.2 Antivirals
    • 5.1.3 Antifungals
    • 5.1.4 Other Products
  • 5.2 By Indication
    • 5.2.1 HIV Infection
    • 5.2.2 Pneumonia
    • 5.2.3 Respiratory Virus Infection
    • 5.2.4 Sepsis
    • 5.2.5 Tuberculosis
    • 5.2.6 Other Indications
  • 5.3 By Distribution Channel
    • 5.3.1 Hospital Pharmacy
    • 5.3.2 Retail Pharmacy
    • 5.3.3 Other Distribution Channels
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 France
      • 5.4.2.2 Germany
      • 5.4.2.3 United Kingdom
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Astellas Pharma Inc
    • 6.1.3 Bayer AG
    • 6.1.4 Bristol-Myers Squibb Company
    • 6.1.5 Gilead Sciences, Inc
    • 6.1.6 GlaxoSmithKline PLC
    • 6.1.7 Merck & Co., Inc.
    • 6.1.8 Novartis AG
    • 6.1.9 Pfizer, Inc
    • 6.1.10 Sanofi SA

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.